Sequent Scientific Limited (SEQUENT) AI Stock Analysis

• Market Cap: ₹54.44B
• Dividend Yield: N/A
• Average Volume (3M): 91.02K
• Price to Earnings (P/E): 180.3
• Beta (1Y): 1.35
• Revenue Growth: 12.33%
• EPS Growth: 439.46%
• Country: IN
• Employees: 1,195
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.57
• Shares Outstanding: 251,762,650
• 10 Day Avg. Volume: 88,736
• 30 Day Avg. Volume: 91,018
• PEG Ratio: -0.99
• Price to Book (P/B): 4.96
• Price to Sales (P/S): 2.25
• P/FCF Ratio: 78.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: ₹215.00 ▲(5.94% Upside)

The overall stock score of 59 reflects a strong recovery in financial performance and positive technical indicators. However, the high P/E ratio suggests overvaluation, which is a significant concern. The absence of earnings call data and corporate events limits further insights.

Sequent Scientific Limited Business Overview & Revenue Model

Company Description

Sequent Scientific Limited (SEQUENT) is a leading integrated pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of veterinary and pharmaceutical products. The company operates primarily in the animal health sector, offering a diverse range of products including formulations, active pharmaceutical ingredients (APIs), and contract manufacturing services. Sequent serves both domestic and international markets, focusing on enhancing the health and well-being of animals while also contributing to food safety and quality in the agricultural sector.

How the Company Makes Money

Sequent Scientific generates revenue through multiple streams, primarily from the sale of its veterinary pharmaceuticals and formulations. The company’s core revenue model is based on manufacturing and selling a variety of animal health products, which includes both product sales and contract manufacturing services for other pharmaceutical companies. Significant partnerships with global players in the veterinary sector enhance its market reach and product offerings. Additionally, Sequent benefits from strategic collaborations and licensing agreements that expand its product portfolio and market access, ultimately contributing to its overall earnings.

Sequent Scientific Limited Financial Statement Overview

Summary

Sequent Scientific Limited has demonstrated a substantial recovery in profitability and cash flow management, with improved operational efficiency reflected in higher margins. However, modest revenue growth and stable leverage ratios suggest a need for strategic expansion and careful debt management.

Income Statement

Sequent Scientific Limited showed a strong recovery in net income from a loss of 358.69 million to a profit of 218.8 million in the latest year, demonstrating significant improvement in profitability. The gross profit margin improved to 47.7% in 2025, a notable increase from 40.5% in 2024. However, the revenue growth rate from 2024 to 2025 was modest at 13.5%, and the EBIT margin was strong at 29.5% in 2025. This indicates a return to operational profitability but highlights slower revenue expansion.

Balance Sheet

The company's debt-to-equity ratio remained stable around 0.68, reflecting moderate leverage. The return on equity (ROE) improved to 3.1% from a negative ROE in the previous year, showing a turnaround in profitability. The equity ratio was 44.0%, suggesting a balanced capital structure. However, the increase in total debt over the past years may pose potential risks if not managed carefully.

Cash Flow

The operating cash flow to net income ratio improved significantly, reflecting improved cash generation relative to profitability. Free cash flow saw a significant rise from negative in 2024 to 442.7 million in 2025, indicating better cash management. However, the free cash flow growth rate is not reliable due to prior negative figures, and consistent positive free cash flow will be essential for financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.03B	15.51B	13.66B	14.18B	14.10B	13.52B
Gross Profit	7.70B	7.40B	5.53B	1.59B	5.66B	6.15B
EBITDA	1.80B	1.59B	549.80M	-464.48M	1.18B	2.06B
Net Income	296.80M	218.80M	-358.69M	-1.21B	409.55M	954.42M
Balance Sheet
Total Assets	0.00	16.02B	15.40B	15.29B	14.51B	13.93B
Cash, Cash Equivalents and Short-Term Investments	630.78M	691.40M	687.85M	416.25M	591.21M	597.03M
Total Debt	0.00	4.81B	4.88B	4.44B	3.65B	2.77B
Total Liabilities	-7.70B	8.32B	8.27B	7.80B	7.11B	6.16B
Stockholders Equity	7.70B	7.04B	6.57B	6.99B	6.92B	7.28B
Cash Flow
Free Cash Flow	0.00	442.70M	-2.12M	-693.71M	-18.69M	619.24M
Operating Cash Flow	0.00	833.60M	305.95M	168.08M	305.95M	1.15B
Investing Cash Flow	0.00	-247.80M	-119.05M	-649.58M	-955.66M	96.48M
Financing Cash Flow	0.00	-607.30M	45.46M	322.28M	672.57M	-1.39B

Sequent Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 202.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SEQUENT, the sentiment is Positive. The current price of 202.95 is below the 20-day moving average (MA) of 210.80, above the 50-day MA of 197.33, and above the 200-day MA of 174.72, indicating a bullish trend. The MACD of 4.92 indicates Negative momentum. The RSI at 58.30 is Neutral, neither overbought nor oversold. The STOCH value of 54.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SEQUENT.

Sequent Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	65 Neutral	₹35.12B	25.64	―	1.67%	5.89%	-1.30%
AARTIDRUGS	62 Neutral	₹44.64B	23.65	―	0.20%	4.08%	31.52%
SEQUENT	59 Neutral	₹54.44B	180.32	―	―	12.33%	439.46%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.14%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPARC	41 Neutral	₹44.39B	-14.87	―	―	-5.57%	23.03%

Sequent Scientific Limited Corporate Events

Sequent Scientific Completes Postal Ballot Dispatch and Prepares for Trading

Sequent Scientific Limited announced the completion of the dispatch of its Postal Ballot Notice, as confirmed by newspaper advertisements in Financial Express and Nava Telangana. The company has also finalized the basis of allotment for its equity shares, with trading set to commence on October 6, 2025, following approval from NSE Emerge. This development marks a significant step in the company’s financial operations, potentially impacting its market presence and stakeholder engagement.

Sequent Scientific Releases Q2 2025 Financial Results

Sequent Scientific Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, in two newspapers, The Financial Express and Nava Telangana. This announcement is part of the company’s compliance with regulatory requirements, providing stakeholders with insights into its financial performance for the specified period.